Weight gain with antipsychotic drugs: The role of the 5-HT2C receptor (HTR2C) and other genes

Pharmacogenetics and Genomics

Volumn 15, Issue 4, 2005, Pages 193-194

  Harrison, Paul J ^a  

^a WARNEFORD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CLOZAPINE; HISTAMINE H1 RECEPTOR; LEPTIN; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; SEROTONIN 2C RECEPTOR;

ALLELE; BINDING AFFINITY; BODY MASS; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DIETARY INTAKE; DRUG RECEPTOR BINDING; ENERGY EXPENDITURE; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; NONHUMAN; OBESITY; PATIENT COMPLIANCE; PATIENT EDUCATION; PHARMACOGENETICS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RISK FACTOR; SHORT SURVEY; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; WEIGHT GAIN;

EID: 17644365724     PISSN: 17446872     EISSN: None     Source Type: Journal    
DOI: 10.1097/01213011-200504000-00001     Document Type: Short Survey

References (18)

1. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 2004; 65:267-272.
2. Taylor DM, McAskill R. Atypical antipsychotics and weight gain - a systematic review. Acta Psychiatr Scand 2000; 101:416-432.
3. Strassing M, Brar JS, Ganguli R. Body mass index and quality of life in community-dwelling patients with schizophrenia. Schizophr Res 2003; 62:73-76.
4. Weiden PJ, Mackell JA, McDonnell DD. Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res 2004; 66:51-57.
5. National Task Force on the Prevention and Treatment of Obesity. Overweight, obesity and health risk. Arch Intern Med 2000; 160: 898-904.
6. Basile VS, Masellis M, Potkin S, Kennedy J. Pharmacogenomics in schizophrenia: the quest for individualized therapy. Hum Mol Genet 2002; 11:2517-2530.
7. Faulkner G, Soundy AA, Lloyd K. Schizophrenia and weight management: a systematic review of interventions to control weight. Acta Psychiatr Scand 2003; 108:324-332.
8. Commuzzie AG, Allison DB. The search for human obesity genes. Science 1998; 280:1374-1377.
9. Templeman LA, Reynolds GP, Arranz A, San L. Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. Pharmacogenetics and Genomics 2005; 15:195-100.
10. Correll CU, Malhotra AK. Pharmacogenetics of antipsychotic-induced weight gain. Psychopharmacology 2004; 174:477-489.
11. Nonogaki K, Strack AM, Dallman MF, Tecott LH. Leptin-independent hyperphagia and type 2 diabetes in mice with a mutated serotonin 5-HT2C receptor gene. Natl Med 1998; 4:1152-1156.
12. 2c receptor gene and their association with obesity and type II diabetes. Diabetologia 2000; 43:373-376.
13. Pooley EC, Fairburn CG, Cooper Z, Sodhi MS, Cowen PJ, Harrison PJ. A 5-HT2C receptor promoter polymorphism (HTR2C - 759C/T) is associated with obesity in women, and with resistance to weight loss in heterozygotes. Am J Med Genet 2004; 126B:124-127.
14. 2C receptor gene polymorphism. Lancet 2002; 359:2086-2087.
15. Von Meyenburg C, Langhans W, Hrupka BJ. Evidence for a role of the 5-HT2C receptor in central lipopolysaccharide- interleukin-1 beta-, and leptin-induced anorexia. Pharmacol Biochem Behav 2003; 74: 1025-1031.
16. 1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 2003; 28:519-526.
17. Arranz MJ, Munro J, Birkett J, Bolonna A, Mancama D, Sodhi M, et al. Pharmacogenetic prediction of clozapine response. Lancet 2000; 355:1615.
18. Meltzer HY, Perry E, Jayathilake K. Clozapine-induced weight gain predicts improvement in psychopathology. Schizophr Res 2003; 59: 19-27.